Pituitary & hypothalamus

A comparison of bilateral internal jugular vein sampling with bilateral inferior petrosal sinus sampling at Mayo Clinic for the subtype evaluation of corticotropin-dependent cushing syndrome

PituitaryPublished Retrospective diagnostic accuracy study

Authors' conclusion

BIPSS is superior to BIJVS for establishing the source of ACTH hypersecretion in ACTH-dependent Cushing syndrome. BIJVS demonstrates limited diagnostic utility in clinical practice.

Study context

Population
Patients with ACTH-dependent Cushing syndrome who underwent simultaneous bilateral inferior petrosal sinus sampling (BIPSS) and bilateral internal jugular vein sampling (BIJVS) at Mayo Clinic (1998–2018); 81 with confirmed diagnoses: 74 Cushing disease (CD), 7 ectopic ACTH-dependent CS81 confirmed diagnoses
Participants
109 patients
Comparison
BIJVS vs BIPSS
Outcome
Sensitivity and specificity using pre- and post-CRH stimulation criteria
Methodological detailssingle-centre, simultaneous BIPSS and BIJVS, 84 patients proceeded to pituitary surgery based on BIPSS results
  • Single-centre
  • Simultaneous BIPSS and BIJVS
  • 84 patients proceeded to pituitary surgery based on BIPSS results

Performance

As reported in the abstract

Diagnostic performance, combined pre- and post-CRH criteria
Test or modelSensitivitySpecificity
BIJVS82%86%
BIPSS100%100%

Sensitivity

BIJVS82%
BIPSS100%

Specificity

BIJVS86%
BIPSS100%

Further findings

OutcomeBIJVSBIPSS
Positive in CD patients at baseline · baseline (pre-CRH)35/74 events68/74 events
Positive in CD patients post-CRH59/74 events72/74 events

Original publication

A comparison of bilateral internal jugular vein sampling with bilateral inferior petrosal sinus sampling at Mayo Clinic for the subtype evaluation of corticotropin-dependent cushing syndrome. Pituitary. Published 22 October 2025. doi:10.1007/s11102-025-01595-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.